3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
5
Phase 2
4
Phase 4
3
Phase 1/2
2
Phase EARLY_PHASE1
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Gastro-enteropancreatic neuroendocrine tumor
1
Acromegaly
1
Interventions
Everolimus
10
lutetium Lu 177 dotatate
7
Magnetic Resonance Spectroscopy
7
pasireotide
4
Specimen Handling
3
Positron Emission Tomography Computed Tomography
3
Nivolumab
3
Ga(III)-DOTATOC
3
Fluorodeoxyglucose F18
3
(177)Lu-DOTA-EB-TATE
3
olaparib
2
gallium Ga 68 dotatate
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Lutetium-177
2
Ipilimumab
2
FAPI-46
2
veliparib
1
vandetanib
1
trifluridine tipiracil drug combination
1
toripalimab
1
tislelizumab
1
talazoparib
1
surufatinib
1
romidepsin
1
peposertib
1
pembrolizumab
1
pelcitoclax
1
pegfilgrastim
1
lanreotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
lanreotide
×
NET
×
Clear all
NCT05364944
2025-11-17
OXTEND-01
Debiopharm International SA
Phase 1
Terminated
19 enrolled